Pharmanovia Acquires Exclusive Rights to Treatment for Parkinson’s Disease
CSL LTD SP/ADR (CSLLY)
NASDAQ:AMEX Investor Relations:
csl.com/investors
Company Research
Source: Business Wire
- The Agreement Covers Australia and New Zealand- Pharmanovia Will Take Over Rights From CSL Seqirus and Will Be Responsible for All Commercial and Regulatory Activities- Deal Strengthens Foothold in Australia and New Zealand and Further Expands Our CNS Portfolio Offering BASILDON, U.K.--(BUSINESS WIRE)--Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines, has today announced the expansion of its neurology portfolio with a new licensing agreement for XADAGO® (safinamide), an add-on treatment for adult patients with idiopathic Parkinson's disease licensed by Zambon, an Italian multinational pharmaceutical company committed to innovating cure and care to make patients’ lives better.The agreement will see Pharmanovia acquire the rights from existing licensee, CSL Seqirus in Australia and New Zealand, with Pharmanovia exclusively responsible for regulatory and commercial activity in
Show less
Read more
Impact Snapshot
Event Time:
CSLLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CSLLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CSLLY alerts
High impacting CSL LTD SP/ADR news events
Weekly update
A roundup of the hottest topics
CSLLY
News
- Transforming pharmaceutical R&D: the impact of digital technologies on drug discovery and development [Yahoo! Finance]Yahoo! Finance
- New Data Presented at IDWeek 2024 Show Adjuvanted and High-Dose Influenza Vaccines are Comparable in Protecting Adults 65 Years of Age and Older Against Seasonal InfluenzaPR Newswire
- CSL Seqirus Presents Data at IDWeek 2024 Highlighting the Urgent Need to Increase Influenza Vaccination Rates and the Benefits of Cell-Based Influenza VaccinesPR Newswire
- CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Sixth BARDA Award in Response to Avian InfluenzaPR Newswire
- CSL Seqirus Presents Real-World Evidence at OPTIONS XII Conference Highlighting Effectiveness of Influenza VaccinationsPR Newswire